Clindamycin phosphate in severe infections mainly caused by Bacteroides fragilis: clinical and microbiological evaluation.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D001442:Bacteroides Infections / Q000188:drug therapy*; D002228:Carbenicillin / Q000627:therapeutic use; D002512:Cephalothin / Q000627:therapeutic use; D002648:Child; D002981:Clindamycin / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D003015:Clostridium Infections / Q000188:drug therapy; D003016:Clostridium perfringens; D004341:Drug Evaluation; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D012480:Salmonella Infections / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D013297:Streptococcus pyogenes
D005839:Gentamicins; D002981:Clindamycin; D002228:Carbenicillin; D002512:Cephalothin